Emerging footprint in large molecules within biotechnology, cell and gene therapies
Global presence in
small-molecule
pharmaceutical ingredients
and
finished dosages
Global presence in
small-molecule pharmaceutical
ingredients and finished
dosages
Best-in-class, future-ready facilities staffed by meritorious personnel
Integrated processes for development, manufacturing, and supply-chain solutions
Committed to sustainable, efficient, and scalable operations
Committed to sustainable, efficient, and scalable operations
Impeccable regulatory
compliance track record
since the
commencement
of
operations.
Impeccable regulatory
compliance track record
since the commencement
of
operations.
Core emphasis on safety, environment, and society.
Core emphasis on safety, environment, and society.
Press releases and announcements
29 Oct 2026
Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences
25 Jul 2026
Newspaper Publication pertaining to financial results for the quarter ended June 30, 2026
24 Jul 2026
Laurus Labs Announces Q1 FY27 Results Revenue at ₹ 2,026 Cr; EBITDA at ₹ 644 Cr, 31.8% margins
24 Jul 2026
Press Release : Financial Results Q1 FY 2027
13 May 2026
Newspaper Publication: Transfer of Shares to Investor Education and Protection Fund Authority
08 May 2026
Newspaper Publication : Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26
02 May 2026
Newspaper Publication pertaining to Financial Results for the quarter and year ended March 31, 2026
30 Apr 2026
Press Note - Laurus Labs Announces Full Year FY26 Results Revenues at ₹6,813 Cr; EBITDA at ₹1,826 Cr, 26.8% margins
30 Apr 2026
Press Release : Financial Results Q4 FY 2026
01 Nov 2025
Newspaper Publication : Regulation 30 of SEBI (LODR ) Regulations 2015
24 Oct 2025
Newspaper Publication pertaining to Financial Results for the quarter and half year ended September 30, 2025
23 Oct 2025
Press Release: Laurus Labs Announces H1 FY26 Results Revenues at ₹ 3,223 Cr, EBITDA at ₹ 818 Cr, 25.4% margins
23 Oct 2025
Press Release: Financial Results Q2 FY 26
26 Jul 2025
Press Note - Newspaper Publication pertaining to Financial Results for the quarter ended June 30, 2025
25 Jul 2025
Press Note - Laurus Labs Announces Q1 FY26 Results Revenues at ₹ 1,570 Cr; EBITDA at ₹ 389 Cr, 24.8% margins
25 Jul 2025
Press Release : Laurus Labs Financial Results Q1 FY 2026
04 Jun 2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May 2025
Newspaper Publication: AGM Notice
09 May 2025
Newspaper Publication : Regulation 30 of SEBI (LODR ) Regulations 2015
25 Apr 2025
Newspaper Publication : Financial Results March 31, 2025
24 Apr 2025
Press Release : Financial Results Q4 FY 2025
27 Jan 2025
Newspaper Advertisement: Financial Results Q3 FY 2025
24 Jan 2025
Laurus Labs Announces 9M FY25 Results Revenues at ₹ 3,834 Cr; EBITDA at ₹ 638 Cr
24 Jan 2025
Press Release - Financial Results Q3 FY 2025
06 Dec 2024
Press Release - Laurus Bio secures equity investments from Eight Roads Ventures, F-Prime Capital and Laurus Labs
25 Oct 2024
Newspaper Advertisement: Financial Results Q2 FY 2025
24 Oct 2024
Press Release - Financial Results Q2 FY 2025
16 Sep 2024
Press Release - Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park
13 Sep 2024
Press Release LaurusLabs concludes successful USFDA Audit for API Manufacturing Facility
13 Sep 2024
Press Release - Laurus Labs Concludes Successful US FDA Audit for API Manufacturing Facility at Hyderabad
02 Sep 2024
Newspaper Advertisement - Notice of Postal Ballot
25 Jul 2024
Press Release - Laurus Labs Announces Q1 FY 25 Results Revenues at ₹ 1,195 Cr; EBITDA at ₹ 171 Cr
25 Apr 2024
Press Release - Financial results for the quarter and year ended March 31, 2024
25 Jan 2024
Press Release - JV Agreement with KRKA
We value your privacy
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic.By Clicking “Accept”, you consent to our use of cookies. Cookie Policy